429 related articles for article (PubMed ID: 26563502)
1. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
2. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
3. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
4. Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI.
Nordström T; Jäderling F; Carlsson S; Aly M; Grönberg H; Eklund M
BMJ Open; 2019 Jun; 9(6):e027816. PubMed ID: 31201191
[TBL] [Abstract][Full Text] [Related]
5. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
[TBL] [Abstract][Full Text] [Related]
6. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
7. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.
Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG;
Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016
[TBL] [Abstract][Full Text] [Related]
8. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H
BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
[TBL] [Abstract][Full Text] [Related]
10. The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.
Fredsøe J; Koetsenruyter J; Vedsted P; Kirkegaard P; Væth M; Edwards A; Ørntoft TF; Sørensen KD; Bro F
PLoS Med; 2020 Feb; 17(2):e1003033. PubMed ID: 32032355
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
12. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
[TBL] [Abstract][Full Text] [Related]
13. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years.
Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H
J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228
[TBL] [Abstract][Full Text] [Related]
14. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
[TBL] [Abstract][Full Text] [Related]
15. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.
Loeb S; Folkvaljon Y; Curnyn C; Robinson D; Bratt O; Stattin P
JAMA Oncol; 2017 Oct; 3(10):1393-1398. PubMed ID: 27768168
[TBL] [Abstract][Full Text] [Related]
16. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
[TBL] [Abstract][Full Text] [Related]
17. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.
Loeb S; Shin SS; Broyles DL; Wei JT; Sanda M; Klee G; Partin AW; Sokoll L; Chan DW; Bangma CH; van Schaik RHN; Slawin KM; Marks LS; Catalona WJ
BJU Int; 2017 Jul; 120(1):61-68. PubMed ID: 27743489
[TBL] [Abstract][Full Text] [Related]
18. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
Sokoll LJ; Sanda MG; Feng Z; Kagan J; Mizrahi IA; Broyles DL; Partin AW; Srivastava S; Thompson IM; Wei JT; Zhang Z; Chan DW
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1193-200. PubMed ID: 20447916
[TBL] [Abstract][Full Text] [Related]
19. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.
Catalona WJ; Partin AW; Sanda MG; Wei JT; Klee GG; Bangma CH; Slawin KM; Marks LS; Loeb S; Broyles DL; Shin SS; Cruz AB; Chan DW; Sokoll LJ; Roberts WL; van Schaik RH; Mizrahi IA
J Urol; 2011 May; 185(5):1650-5. PubMed ID: 21419439
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.
Brait M; Banerjee M; Maldonado L; Ooki A; Loyo M; Guida E; Izumchenko E; Mangold L; Humphreys E; Rosenbaum E; Partin A; Sidransky D; Hoque MO
Oncotarget; 2017 Feb; 8(9):15431-15440. PubMed ID: 28147335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
